Verve Therapeutics, Inc. (VERV)

5.73

+0.44

+(8.32%)

At close: June 5 at 4:00:01 PM EDT

5.90

+0.17

+(2.97%)

Pre-Market: 8:49:37 AM EDT

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

The consensus price target hints at a 367.9% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 23 hours ago

VERV
+8.32%
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to pu

GlobeNewswire 3 days ago

VERV
+8.32%
Verve Therapeutics to Participate in Upcoming Investor Conferences

BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NYGoldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL Live webcasts will be a

GlobeNewswire 9 days ago

VERV
+8.32%
3 Top Genomics Stocks to Add to Your Portfolio in 2025

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Zacks 15 days ago

VERV
+8.32%

CRSP
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks

As the U.S. market navigates a mixed landscape with rising Treasury yields and a recent credit rating downgrade, investors are increasingly looking for opportunities that balance risk and reward. Penny stocks, often overlooked, continue to offer potential growth avenues particularly when they are underpinned by strong financials. These smaller or newer companies can present unique opportunities for those willing to explore beyond the mainstream indices, and we'll highlight three promising...

Simply Wall St. 17 days ago

LDI

KIND

VERV
+8.32%
Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...

Simply Wall St. 18 days ago

VERV
+8.32%
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 50.70% and 362.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 23 days ago

VERV
+8.32%

PSTV
Verve Therapeutics: Q1 Earnings Snapshot

BOSTON (AP) — Verve Therapeutics Inc. VERV) on Wednesday reported a loss of $31 million in its first quarter. The Boston-based company said it had a loss of 35 cents per share.

Associated Press Finance 23 days ago

VERV
+8.32%
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketable

GlobeNewswire 23 days ago

VERV
+8.32%
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Take Verve Therapeutics (NASDAQ: VERV), a small-cap, clinical-stage biotech. If Verve Therapeutics has any chance of soaring by more than 300% in the next year, the company will have to impress the market with its leading candidate, VERVE-102. Notably, Verve Therapeutics recently announced positive results from a Phase 1b clinical trial for VERVE-102 as a potential treatment for heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease.

Motley Fool last month

VERV
+8.32%
Why Verve Therapeutics Zoomed 40% Higher This Week

Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (NASDAQ: VERV) big stock price leap this week. Verve is a clinical-stage biotech, so its success depends on how it's progressing with its pipeline. The indications were quite encouraging this week when the company published initial data from a phase 1b clinical trial of VERVE-102, a drug targeting heterozygous familial hypercholesterolemia (HeFH) -- a genetic disorder that causes high cholesterol levels -- and premature coronary artery disease.

Motley Fool last month

VERV
+8.32%
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.

Zacks last month

VERV
+8.32%

CELG-RT

IRWD
Why Verve Therapeutics Is Skyrocketing Today

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy.

Motley Fool last month

VERV
+8.32%
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.

Zacks last month

VERV
+8.32%

LLY
Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Over the last 7 days, the United States market has risen 6.8%, and over the past 12 months, it is up 5.9%, with earnings forecasted to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value in such a buoyant market environment. By focusing on stocks with strong financial foundations and clear growth potential, investors may uncover opportunities that balance risk with promising...

Simply Wall St. last month

UAMY

VERV
+8.32%

CLOV
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Pharmaceutical Technology last month

LLY

VERV
+8.32%
This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped Monday.

Barrons.com last month

VERV
+8.32%

LLY
Top Premarket Gainers

Third Harmonic Bio (THRD) shares rose 40% in recent Monday premarket activity, after saying its boar

PREMIUM
MT Newswires last month

AAPL

THRD

VERV
+8.32%
Verve’s second swing at gene editing for heart disease shows early promise

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety concerns — at least so far.

BioPharma Dive last month

VERV
+8.32%
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second

GlobeNewswire last month

VERV
+8.32%

Performance Overview

Return	VERV	S&P 500 (^GSPC)
AAJ	+1.60%	+0.98%
1-Year	+7.30%	+10.93%
3-Year	-60.70%	+44.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Breaking

Verve Therapeutics, Inc. (VERV)

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics to Participate in Upcoming Investor Conferences

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Verve Therapeutics: Q1 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Why Verve Therapeutics Zoomed 40% Higher This Week

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

Why Verve Therapeutics Is Skyrocketing Today

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

Top Premarket Gainers

Verve’s second swing at gene editing for heart disease shows early promise

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Performance Overview